Rising drug cost impacts on cost-effectiveness of 2 chemotherapy regimens for intermediate-risk rhabdomyosarcoma: A report from the Children's Oncology Group.

Russell, Heidi V; Chi, Yueh-Yun; Okcu, M Fatih; Bernhardt, M Brooke; Rodriguez-Galindo, Carlos; Gupta, Abha A; Hawkins, Douglas S

Russell, Heidi V; Chi, Yueh-Yun; Okcu, M Fatih; Bernhardt, M Brooke; Rodriguez-Galindo, Carlos; Gupta, Abha A; Hawkins, Douglas S.

Afiliación

Russell HV; Texas Children's Cancer Center, Baylor College of Medicine, Houston, Texas.
Chi YY; Center for Medical Ethics and Health Policy, Baylor College of Medicine, Houston, Texas.
Okcu MF; Department of Pediatrics and Preventative Medicine, University of Southern California, Los Angeles, California.
Bernhardt MB; Texas Children's Cancer Center, Baylor College of Medicine, Houston, Texas.
Rodriguez-Galindo C; Texas Children's Cancer Center, Baylor College of Medicine, Houston, Texas.
Gupta AA; St. Jude Children's Research Hospital, Memphis, Tennessee.
Hawkins DS; Hospital for Sick Children, Toronto, Ontario, Canada.

Cancer ; 128(2): 317-325, 2022 Jan 15.

Article en En | MEDLINE | ID: mdl-34623638

Asunto(s)

Protocolos de Quimioterapia Combinada Antineoplásica/economía; Costos de los Medicamentos; Rabdomiosarcoma; Niño; Análisis Costo-Beneficio; Ciclofosfamida/economía; Dactinomicina/economía; Humanos; Rabdomiosarcoma/tratamiento farmacológico; Vincristina/economía

Palabras clave

cancer; chemotherapy; child; cost-effectiveness; rhabdomyosarcoma

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Rabdomiosarcoma / Protocolos de Quimioterapia Combinada Antineoplásica / Costos de los Medicamentos Tipo de estudio: Clinical_trials / Etiology_studies / Guideline / Health_economic_evaluation / Prognostic_studies / Risk_factors_studies Límite: Child / Humans Idioma: En Revista: Cancer Año: 2022 Tipo del documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google